Makoto Matsumoto

Makoto Matsumoto

Auto-generated profile, based on publicly available information

Makoto Matsumoto

Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba-shi, Japan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2025 in Leukemia
Verified
Journal Article
Open access
PDF file
SIShintaro Izumi
Shintaro Izumi
KOKo Ohtani
Ko Ohtani
MMMakoto Matsumoto
Makoto Matsumoto
SSSeito Shibata
Seito Shibata
BRBahityar Rahmutulla
Bahityar Rahmutulla
THTakayuki Hoshii
Takayuki Hoshii
Histone H3 lysine 4 trimethylation (H3K4me3) is abundant in mixed-lineage leukemia-rearranged (MLL-r) acute myeloid leukemia (AML) cells; however, the responsible enzymes and their roles remain unclear. This study aimed to identify the modifier responsible for high H3K4me3 modification in MLL-r leukemia and its downstream targets essential for the cell proliferation. Here, we performed a CRISPR-tiling screen against known H3K4 methylation modifiers in an MLL-r AML model. Disrupting the SETD1B catalytic SET domain caused depletion of FLT3-ITD or NrasG12D-expressing AML cells, and gene expression downregulation, particularly in the MYC pathway. SETD1B SET domain loss results in a significant decrease in H3K4me3 breadth. Exogenous MYC expression or disrupting H3K4 demethylase KDM5C significantly restored growth defects in SETD1B SET domain-mutant cells. These data indicated that SETD1B was required for H3K4me3 breadth and MYC expression. Thus, a thorough understanding of SETD1B-mediated H3K4me3 breadth is critical for developing markers and therapies for MYC-dependent leukemia subtypes.

3 August 2023 in EMBO Reports
Verified
Journal Article
Closed access
SPSarah Perlee
Sarah Perlee
SKSota Kikuchi
Sota Kikuchi
TNTomoyoshi Nakadai
Tomoyoshi Nakadai
TMTakeshi Masuda
Takeshi Masuda
SOSumio Ohtsuki
Sumio Ohtsuki
THTakayuki Hoshii
Takayuki Hoshii

23 August 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MNMeng Ning
Meng Ning
THTakayuki Hoshii
Takayuki Hoshii
TNTakuya Nakagawa
Takuya Nakagawa
GUGenki Usui
Genki Usui
SIShintaro Izumi
Shintaro Izumi
AKAtsushi Kaneda
Atsushi Kaneda
SETD1A is a member of the KMT2 histone H3K4 methyltransferase family of mammalian proteins. Aberrant SETD1A expression is associated with a poor prognosis in patients with gastric cancer (GC). We found that the catalytic domain of SETD1A is nonessential for GC cell proliferation, whereas the non-catalytic FLOS domain is essential. The loss of SETD1A commonly reduces the expression of E2F target genes in GC cell lines from the three independent molecular subtypes. A pooled CRISPR screen and cDNA rescue experiment showed that TAF6 acts downstream of SETD1A’s non-catalytic function, which is essential for GC cell proliferation. Both SETD1A and TAF6 are required for G1/S cell cycle progression in GC cells. The mRNA expression of E2F4 highly correlated with both the SETD1A and TAF6 expression in patients with GC. Notably, E2F4 supported the expression of TAF6 but not that of SETD1A, suggesting that E2F4 serves as a coregulator of SETD1A, which is involved in regulating TAF6. These results demonstrate that the non-canonical roles of SETD1A and its downstream pathways are crucial for cell cycle progression in GC.